Document is current
Any future updates will be listed below
-
Authors
Rodrigues, Bárbara https://orcid.org/0000-0003-4698-962X
Sousa, Vanessa https://orcid.org/0000-0002-5855-1863
Yrigollen, Carolyn M. https://orcid.org/0000-0002-2399-6176
Tassone, Flora https://orcid.org/0000-0002-6388-9180
Villate, Olatz https://orcid.org/0000-0002-5574-837X
Allen, Emily G. https://orcid.org/0000-0003-0963-036X
Glicksman, Anne
Tortora, Nicole
Nolin, Sarah L. https://orcid.org/0000-0001-5209-289X
Nogueira, António J. A. https://orcid.org/0000-0001-7089-2508
Jorge, Paula https://orcid.org/0000-0002-6507-222X
-
Funding
Funding for this research was provided by:
Fundação para a Ciência e a Tecnologia (SFRH/BD/136398/2018, EXPL/BIA-REP/0423/2021, UIDP/50017/2020+UIDB/50017/2020)
- License Information
-
More Information
Article History
Received: 14 July 2023
Accepted: 9 May 2024
First Online: 21 June 2024
Declarations
:
: Informed consent was obtained from all participants within previously published studies. Participants of set 1 the informed consent approved by the clinical ethical committee of Cruces Hospital was obtained in all cases prior to genetic testing. Protocols and consent forms of participants in set 2 were conducted in concordance with the Belmont Report and approved by the Institutional Review Board at Emory University, and written informed consent was obtained from all subjects (IRB00045808). Participants of the set 3 were recruited through the Fragile X Research and Treatment Center at the MIND Institute – University of California Davis, USA. Whole blood was collected according to protocols approved by the Institutional Review Board at the University of California, Davis, and informed consent was obtained from all patients. This research was approved from the Ethics Committee of the Unidade Local de Saúde de Santo António (2020.119 /097-DEFI/099-CE) as part of B. Rodrigues’s Ph.D. studies.
: Not Applicable.
: The authors declare no competing interests.
